Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China.
Clin Nucl Med. 2021 Sep 1;46(9):732-737. doi: 10.1097/RLU.0000000000003760.
68Ga-pentixafor PET/CT was reported to have a high sensitivity in detecting tumor involvement of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) in our previous study. We aimed to further investigate its value in response assessment in WM/LPL.
Fifteen patients with WM/LPL were recruited in a prospective cohort study and underwent both 68Ga-pentixafor and 18F-FDG PET/CT at baseline and posttreatment. PET/CT-based responses were analyzed with visual assessments and compared with clinical response.
At baseline, all of the 15 patients had a positive 68Ga-pentixafor PET/CT scan, whereas 18F-FDG PET/CT was positive in 11/15 patients. After chemotherapy, the overall response rate was 86.7% (13/15), and 68Ga-pentixafor PET/CT showed different degree of tumor response from baseline in these patients. In the 2 patients with progressive disease, 68Ga-pentixafor PET/CT detected new lesions or remarkable increase of 68Ga-pentixafor uptake in tumor involvements. However, 18F-FDG PET/CT failed to detect the improvement of disease in 6/13 patients and missed disease progression in 1 of the 2 patients.
68Ga-pentixafor PET/CT outperformed 18F-FDG PET/CT in response assessment of WM/LPL.
在我们之前的研究中，68Ga-戊替索昔夫 PET/CT 被报道在检测华氏巨球蛋白血症/淋巴浆细胞淋巴瘤（WM/LPL）肿瘤累及方面具有很高的灵敏度。我们旨在进一步研究其在 WM/LPL 反应评估中的价值。
15 例 WM/LPL 患者入组前瞻性队列研究，在基线和治疗后均行 68Ga-戊替索昔夫和 18F-FDG PET/CT 检查。通过视觉评估分析 PET/CT 结果，并与临床反应进行比较。
在基线时，所有 15 例患者的 68Ga-戊替索昔夫 PET/CT 扫描均为阳性，而 18F-FDG PET/CT 阳性者为 11/15 例。化疗后，总缓解率为 86.7%（13/15），这些患者的 68Ga-戊替索昔夫 PET/CT 显示出不同程度的肿瘤反应。在 2 例疾病进展的患者中，68Ga-戊替索昔夫 PET/CT 检测到新病变或肿瘤累及部位 68Ga-戊替索昔夫摄取显著增加。然而，在 13 例中有 6 例患者的 18F-FDG PET/CT 未能检测到疾病改善，2 例中有 1 例漏诊疾病进展。
68Ga-戊替索昔夫 PET/CT 在 WM/LPL 的反应评估中优于 18F-FDG PET/CT。
Zotero 插件